-
Something wrong with this record ?
Peroxisome proliferator-activated receptors in regulation of cytochromes P450: new way to overcome multidrug resistance?
K. Cizkova, A. Konieczna, B. Erdosova, R. Lichnovska, J. Ehrmann,
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
NLK
Free Medical Journals
from 2001
PubMed Central
from 2001 to 2012
Europe PubMed Central
from 2001 to 2012
ProQuest Central
from 2007-01-01 to 2012
Open Access Digital Library
from 2001-01-01 to 2012-12-31
Open Access Digital Library
from 2001-01-01 to 2012-11-27
Open Access Digital Library
from 2001-01-01
CINAHL Plus with Full Text (EBSCOhost)
from 2006-01-01 to 2012-01-31
Medline Complete (EBSCOhost)
from 2006-01-01 to 2012-01-31
Health & Medicine (ProQuest)
from 2007-01-01 to 2012
ROAD: Directory of Open Access Scholarly Resources
from 2000 to 2012
PubMed
23193364
DOI
10.1155/2012/656428
Knihovny.cz E-resources
- MeSH
- Models, Biological MeSH
- Drug Resistance, Neoplasm * MeSH
- Humans MeSH
- Drug Resistance, Multiple * MeSH
- Peroxisome Proliferator-Activated Receptors metabolism MeSH
- Cytochrome P-450 Enzyme System metabolism MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
Embryonic and tumour cells are able to protect themselves against various harmful compounds. In human pathology, this phenomenon exists in the form of multidrug resistance (MDR) that significantly deteriorates success of anticancer treatment. Cytochromes P450 (CYPs) play one of the key roles in the xenobiotic metabolism. CYP expression could contribute to resistance of cancer cells to chemotherapy. CYP epoxygenases (CYP2C and CYP2J) metabolize about 20% of clinically important drugs. Besides of drug metabolism, CYP epoxygenases and their metabolites play important role in embryos, normal body function, and tumors. They participate in angiogenesis, mitogenesis, and cell signaling. It was found that CYP epoxygenases are affected by peroxisome proliferator-activated receptor α (PPARα). Based on the results of current studies, we assume that PPARs ligands may regulate CYP2C and CYP2J and in some extent they may contribute to overcoming of MDR in patients with different types of tumours.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc13024095
- 003
- CZ-PrNML
- 005
- 20130710095719.0
- 007
- ta
- 008
- 130703s2012 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1155/2012/656428 $2 doi
- 035 __
- $a (PubMed)23193364
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Cizkova, Katerina $u Department of Histology and Embryology, Faculty of Medicine and Dentistry, Palacky University, Hnevotinska 3, 775 15 Olomouc, Czech Republic. keri@email.cz
- 245 10
- $a Peroxisome proliferator-activated receptors in regulation of cytochromes P450: new way to overcome multidrug resistance? / $c K. Cizkova, A. Konieczna, B. Erdosova, R. Lichnovska, J. Ehrmann,
- 520 9_
- $a Embryonic and tumour cells are able to protect themselves against various harmful compounds. In human pathology, this phenomenon exists in the form of multidrug resistance (MDR) that significantly deteriorates success of anticancer treatment. Cytochromes P450 (CYPs) play one of the key roles in the xenobiotic metabolism. CYP expression could contribute to resistance of cancer cells to chemotherapy. CYP epoxygenases (CYP2C and CYP2J) metabolize about 20% of clinically important drugs. Besides of drug metabolism, CYP epoxygenases and their metabolites play important role in embryos, normal body function, and tumors. They participate in angiogenesis, mitogenesis, and cell signaling. It was found that CYP epoxygenases are affected by peroxisome proliferator-activated receptor α (PPARα). Based on the results of current studies, we assume that PPARs ligands may regulate CYP2C and CYP2J and in some extent they may contribute to overcoming of MDR in patients with different types of tumours.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a systém (enzymů) cytochromů P-450 $x metabolismus $7 D003577
- 650 12
- $a mnohočetná léková rezistence $7 D018432
- 650 12
- $a chemorezistence $7 D019008
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a biologické modely $7 D008954
- 650 _2
- $a receptory aktivované proliferátory peroxizomů $x metabolismus $7 D047492
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Konieczna, Anna $u -
- 700 1_
- $a Erdosova, Bela $u -
- 700 1_
- $a Lichnovska, Radka $u -
- 700 1_
- $a Ehrmann, Jiri $u -
- 773 0_
- $w MED00008233 $t Journal of biomedicine & biotechnology $x 1110-7251 $g Roč. 2012(2012), s. 656428
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/23193364 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20130703 $b ABA008
- 991 __
- $a 20130710100142 $b ABA008
- 999 __
- $a ok $b bmc $g 987775 $s 822475
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2012 $b 2012 $d 656428 $i 1110-7251 $m Journal of biomedicine and biotechnology $n J Biomed Biotechnol $x MED00008233
- LZP __
- $a Pubmed-20130703
